Zentalis Pharmaceuticals (ZNTL) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability
2. 02We have incurred significant net losses since inception, and we expect to continue to incur significant net losses for the foreseeable future
3. 03Our ability to generate product revenue and achieve profitability depends significantly on our ability to achieve a number of objectives
4. 04We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

1. 05We are substantially dependent on the success of azenosertib, which is currently our only product candidate in clinical development. If we are unable to complete development of, obtain approval for and commercialize azenosertib in a timely manner, our business will be harmed
2. 06market or promote any product candidate before we receive marketing approval from the FDA and/or ex-U.S. regulatory authorities, and we may never receive such marketing approvals
3. 07We have and in the future may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any of these collaborations is not successful, we may not be able to capitalize on the market potential of those product candidates
4. 08Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability
5. 09This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects
6. 10The clinical trials of azenosertib or any future product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA or ex-U.S. regulatory authorities or otherwise produce positive results
7. 11Interim, initial, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
8. 12prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock
9. 13Even if approved, azenosertib and any future product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success
10. 14If we experience delays or difficulties in the enrollment and/or continuing participation of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected
11. 15A fast track designation from the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval
12. 16We are developing azenosertib in combination with other therapies, which exposes us to additional risks
13. 17If the market opportunity for azenosertib or any future product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer
14. 18We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted
15. 19We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
16. 20Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
17. 21Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition
18. 22Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 23patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors
2. 24The FDA and ex-U.S. regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
3. 25Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
4. 26Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight
5. 27The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate product revenue and could require us to expend significant time and resources in response and could generate negative publicity
6. 28The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
7. 29critical activities. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations
8. 30We may face difficulties from changes to current regulations and future legislation
9. 31Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to fraud and abuse laws and other healthcare laws and regulations
10. 32Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition
11. 33Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
12. 34If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business
13. 35Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 36Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 37If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
3. 38In order to successfully implement our long-term plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
4. 39Our business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity
5. 40Ex-U.S. pricing, drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states
6. 41Unfavorable U.S., global, political or economic conditions could adversely affect our business, financial condition or results of operations
7. 42Increasing scrutiny and changing expectations from governments and other stakeholders with respect to ESG policies and practices may cause us to incur additional costs or expose us to additional risks
8. 43Business interruptions could adversely affect our operations
9. 44Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
10. 45A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
11. 46If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
12. 47The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention
13. 48due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected

Risks Related to Our Intellectual Property

1. 49Our success depends on our ability to protect our intellectual property and our proprietary platform
2. 50If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
3. 51If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business
4. 52If the scope of any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
5. 53alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects
6. 54The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties
7. 55Intellectual property rights do not necessarily address all potential threats to our competitive advantage
8. 56Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
9. 57We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our issued patents or the patents of our licensors could be found invalid or unenforceable if challenged in court
10. 58Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
11. 59Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
12. 60Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our or our licensors' patent applications and the enforcement or defense of our or our licensors' issued patents
13. 61Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
14. 62We or our licensors may be subject to claims challenging the inventorship or ownership of our or our licensors' patents and other intellectual property
15. 63Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
16. 64If we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed
17. 65We may not be able to protect our intellectual property rights throughout the world
18. 66Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
19. 67If we are unable to protect our trade secrets, our business and competitive position would be harmed
20. 68We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks Related to Our Dependence on Third Parties

1. 69If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans

Risks Related to Ownership of Our Common Stock

1. 70The price of our stock may be volatile, and you could lose all or part of your investment
2. 71Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
3. 72Our principal stockholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval
4. 73Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
5. 74Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us
6. 75If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
7. 76Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
8. 77We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock
9. 78We may be subject to securities litigation, which is expensive and could divert management attention